Visual field defect and intracerebral hemorrhage associated with use of vardenafil (Levitra).
McGee
Hall T
HT
Casey Eye Institute, Department of Ophthalmology, Oregon Health and Science University, Portland, OR 97201, USA.
Egan
Robert A
RA
Clark
Wayne M
WM
D000368:Aged; D002533:Cerebral Angiography; D002536:Cerebral Arteries / Q000000981:diagnostic imaging / Q000187:drug effects / Q000473:pathology; D002543:Cerebral Hemorrhage / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D006423:Hemianopsia / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D006801:Humans; D007093:Imidazoles / Q000009:adverse effects*; D008297:Male; D010296:Parietal Lobe / Q000098:blood supply / Q000187:drug effects / Q000503:physiopathology; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects*; D010879:Piperazines / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects; D014057:Tomography, X-Ray Computed; D014227:Triazines / Q000009:adverse effects; D000069058:Vardenafil Dihydrochloride; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology; D014794:Visual Fields / Q000187:drug effects
D007093:Imidazoles; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D013450:Sulfones; D014227:Triazines; D000069058:Vardenafil Dihydrochloride